Prognostic significance of Klotho expression in patients with renal cell carcinoma.

IF 0.8 Q4 UROLOGY & NEPHROLOGY Urologia Journal Pub Date : 2024-08-01 Epub Date: 2024-05-10 DOI:10.1177/03915603241248303
Kumar Rajiv Ranjan, Shrawan Kumar Singh, Nandita Kakkar, Ravimohan Mavuduru
{"title":"Prognostic significance of Klotho expression in patients with renal cell carcinoma.","authors":"Kumar Rajiv Ranjan, Shrawan Kumar Singh, Nandita Kakkar, Ravimohan Mavuduru","doi":"10.1177/03915603241248303","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Various molecular markers have been investigated in renal cell carcinoma (RCC) without significant reliability. We analyzed Klotho (tumor suppressive protein) expression in RCC to investigate its association with tumor-stage, grade, disease-free-survival (DFS) and overall-survival (OS).</p><p><strong>Methods: </strong>Data of histologically confirmed patients of RCC with complete clinical follow-up were retrieved from Medical-Record-Library. Tissue sections of tumor and normal parenchyma were prepared from the blocks. Immunohistochemical studies for Klotho were done with commercially available kit (EPR6856, Ab181373; Abcam, Cambridge MA, USA). Klotho expression was scored between 0-3 and grouped into weak/absent (0, 1) and moderate/strong (2, 3). Tumors stages and grades were grouped into low stage (I and II) and high stage (III and IV) and into low grade (grade 1 and 2) and high grade (grade 3 and 4) according to WHO/ISUP grading. The histopathologists were blinded as to the clinical and follow-up data. Various prognostic factors were analyzed with respect to Klotho expression. Kaplan-Meier curves were created for DFS and OS.</p><p><strong>Results: </strong>Fifty-four patients of mean age 55.15 ± 13.34 years and M:F ratio of 1.8:1 were included. Normal renal tissue had strong expression of Klotho in all. In tumor tissue 20 (37%) had negative, 7 (13%) had weak, 14 (25.9%) had moderate and 13 (24.1%) had strong Klotho expression. Significantly more patients had absent/weak Klotho expression with higher grade (16/24 (66.7%) vs 7/25 (28%); <i>p</i> = 0.007), higher stage (22/33 (66%) vs 5/21 (23.8%); <i>p</i> = 0.002), LVI (12/14 (85.7%) vs 2/14 (14.3%); <i>p</i> = 0.002), sinus-fat-invasion (16/21 (76.2%) vs 5/21 (23.8%); <i>p</i> = 0.002), renal-vein-involvement (14/18 (77.8%) vs 4/18 (22.2%); <i>p</i> = 0.004), necrosis (17/26 (65.3%) vs 9/26 (34.6%); <i>p</i> = 0.029) and metastasis (8/9 (88.9%) vs 1/9 (11.1%); <i>p</i> = 0.01). Median DFS and OS were significantly lower in patients with weak/absent Klotho expression (12 vs 23 months, <i>p</i> = 0.023 and 15 vs 33 months, <i>p</i> = 0.006 respectively). Kaplan-Meier curves showed lower estimated DFS and OS in patients with weak/absent expression.</p><p><strong>Conclusions: </strong>We conclude that Klotho expression in renal tumor could be a good prognostic marker in patients with RCC.</p>","PeriodicalId":23574,"journal":{"name":"Urologia Journal","volume":" ","pages":"494-499"},"PeriodicalIF":0.8000,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Urologia Journal","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1177/03915603241248303","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/5/10 0:00:00","PubModel":"Epub","JCR":"Q4","JCRName":"UROLOGY & NEPHROLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Introduction: Various molecular markers have been investigated in renal cell carcinoma (RCC) without significant reliability. We analyzed Klotho (tumor suppressive protein) expression in RCC to investigate its association with tumor-stage, grade, disease-free-survival (DFS) and overall-survival (OS).

Methods: Data of histologically confirmed patients of RCC with complete clinical follow-up were retrieved from Medical-Record-Library. Tissue sections of tumor and normal parenchyma were prepared from the blocks. Immunohistochemical studies for Klotho were done with commercially available kit (EPR6856, Ab181373; Abcam, Cambridge MA, USA). Klotho expression was scored between 0-3 and grouped into weak/absent (0, 1) and moderate/strong (2, 3). Tumors stages and grades were grouped into low stage (I and II) and high stage (III and IV) and into low grade (grade 1 and 2) and high grade (grade 3 and 4) according to WHO/ISUP grading. The histopathologists were blinded as to the clinical and follow-up data. Various prognostic factors were analyzed with respect to Klotho expression. Kaplan-Meier curves were created for DFS and OS.

Results: Fifty-four patients of mean age 55.15 ± 13.34 years and M:F ratio of 1.8:1 were included. Normal renal tissue had strong expression of Klotho in all. In tumor tissue 20 (37%) had negative, 7 (13%) had weak, 14 (25.9%) had moderate and 13 (24.1%) had strong Klotho expression. Significantly more patients had absent/weak Klotho expression with higher grade (16/24 (66.7%) vs 7/25 (28%); p = 0.007), higher stage (22/33 (66%) vs 5/21 (23.8%); p = 0.002), LVI (12/14 (85.7%) vs 2/14 (14.3%); p = 0.002), sinus-fat-invasion (16/21 (76.2%) vs 5/21 (23.8%); p = 0.002), renal-vein-involvement (14/18 (77.8%) vs 4/18 (22.2%); p = 0.004), necrosis (17/26 (65.3%) vs 9/26 (34.6%); p = 0.029) and metastasis (8/9 (88.9%) vs 1/9 (11.1%); p = 0.01). Median DFS and OS were significantly lower in patients with weak/absent Klotho expression (12 vs 23 months, p = 0.023 and 15 vs 33 months, p = 0.006 respectively). Kaplan-Meier curves showed lower estimated DFS and OS in patients with weak/absent expression.

Conclusions: We conclude that Klotho expression in renal tumor could be a good prognostic marker in patients with RCC.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
肾细胞癌患者 Klotho 表达的预后意义。
导言:对肾细胞癌(RCC)的各种分子标记物进行了研究,但并不十分可靠。我们分析了 Klotho(肿瘤抑制蛋白)在 RCC 中的表达,研究其与肿瘤分期、分级、无病生存期(DFS)和总生存期(OS)的关系:方法:从医学文献数据库(Medical-Record-Library)中检索经组织学确诊并有完整临床随访的 RCC 患者数据。制备肿瘤和正常实质组织切片。使用市售试剂盒(EPR6856, Ab181373; Abcam, Cambridge MA, USA)对 Klotho 进行免疫组化检测。Klotho 表达在 0-3 之间,分为弱/无(0,1)和中/强(2,3)。根据 WHO/ISUP 分级,肿瘤分期和分级分为低分期(I 期和 II 期)和高分期(III 期和 IV 期),以及低分级(1 级和 2 级)和高分级(3 级和 4 级)。组织病理学家对临床和随访数据均为盲人。分析了与Klotho表达有关的各种预后因素。对DFS和OS绘制了Kaplan-Meier曲线:54名患者的平均年龄为(55.15 ± 13.34)岁,男女比例为1.8:1。所有正常肾组织都有 Klotho 的强表达。在肿瘤组织中,20 例(37%)Klotho 表达为阴性,7 例(13%)为弱表达,14 例(25.9%)为中度表达,13 例(24.1%)为强表达。Klotho表达缺失/弱的患者明显多于分级较高(16/24 (66.7%) vs 7/25 (28%);P = 0.007)、分期较高(22/33 (66%) vs 5/21 (23.8%);P = 0.002)、LVI(12/14 (85.7%) vs 2/14 (14.3%);P = 0.002)、窦脂肪浸润(16/21(76.2%) vs 5/21(23.8%);p = 0.002)、肾静脉浸润(14/18(77.8%) vs 4/18(22.2%);p = 0.004)、坏死(17/26(65.3%) vs 9/26(34.6%);p = 0.029)和转移(8/9(88.9%) vs 1/9(11.1%);p = 0.01)。Klotho弱/无表达患者的中位生存期和手术期明显较低(分别为12个月 vs 23个月,p = 0.023和15个月 vs 33个月,p = 0.006)。Kaplan-Meier曲线显示,弱/无表达患者的估计DFS和OS较低:我们得出结论:肾肿瘤中 Klotho 的表达可作为 RCC 患者的良好预后标志物。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Urologia Journal
Urologia Journal UROLOGY & NEPHROLOGY-
CiteScore
0.60
自引率
12.50%
发文量
66
期刊最新文献
Risk factors for benign uretero-enteric anastomotic strictures after open radical cystectomy and ileal conduit. On integrative analysis of multi-level gene expression data in Kidney cancer subgrouping. A new approach to repair recurrent vescicourethral anastomotic strictures after radical prostatectomy: The use of prerectal access. Potential value of Prostate Cancer Antigen 3 score in prediction of final cancer pathology parameters in radical prostatectomy patients. Retrograde urethrography (RUG) combined with voiding cystourethrography (VCUG) versus surgical findings in assessment of urethral strictures length.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1